TB mRNA Vaccine2022-06-10T06:17:44+00:00

Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain.

About Tuberculosis mRNA Vaccine

Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease. If not treated properly, TB disease can be fatal.

Source: CDC

A total of 1.5 million people died from TB in 2020 (including 214 000 people with HIV). Worldwide, TB is the 13th leading cause of death and the second leading infectious killer after COVID-19 (above HIV/AIDS). In 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. 5.6 million men, 3.3 million women and 1.1 million children. TB is present in all countries and age groups. But TB is curable and preventable. In 2020, 1.1 million children fell ill with TB globally. Child and adolescent TB is often overlooked by health providers and can be difficult to diagnose and treat. In 2020, the 30 high TB burden countries accounted for 86% of new TB cases. Eight countries account for two thirds of the total, with India leading the count, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa. Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat. Only about one in three people with drug resistant TB accessed treatment in 2020.

Source: WHO

Tuberculosis mRNA Vaccine Pipeline

DEVELOPMENT

PRECLINCAL

PHASE 1

PHASE 2

PHASE 3

INDICATION
Tuberculosis mRNA Vaccine (TB-mRNA)

GLOBAL PUBLIC HEALTH IMPACT
Prophylactic mRNA Vaccine. Therapeutic mRNA Vaccine

PARTNERS / SUPPORTERS
mRNA UCV Consortium

COMMERCIAL
Normax

LICENSING
Vaxcomm

Tb mRNA Vaccine Pipeline

DEVELOPMENT

INDICATION
Tuberculosis mRNA Vaccine

TECHNOLOGY
Prophylactic mRNA Vaccine. Therapeutic mRNA Vaccine

PARTNERS / SUPPORTERS
mRNA UCV Consortium

COMMERCIAL
Normax

LICENSING
Vaxcomm

Pricing

Our goal is to be able to mass-produce a vaccine that is both highly efficient and affordable for the general public, that we will be able to distribute at the cost of only $4 per dose.

The per-patient cost of hospitalization of drug-susceptible cases ranged from $10,100 to $45,400, with an average of $24,000.

Source: NLM

Go to Top